Mechanism-based concepts of size and maturity in pharmacokinetics

被引:874
作者
Anderson, B. J. [1 ]
Holford, N. H. G. [2 ]
机构
[1] Univ Auckland, Sch Med, Dept Anaesthesiol, Auckland 1, New Zealand
[2] Univ Auckland, Sch Med, Dept Pharmacol & Clin Pharmacol, Auckland 1, New Zealand
关键词
allometry; weight; growth; maturation; postmenstrual age;
D O I
10.1146/annurev.pharmtox.48.113006.094708
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Growth and development can be investigated using readily observable demographic factors such as weight and age. Size is the primary covariate and can be referenced to a 70-kg person with allometry using a coefficient of 0.75 for clearance and 1 for volume. The use of these coefficients is supported by fractal geometric concepts and observations from diverse areas in biology. Fat free mass (FFM) might be expected to do better than total body weight when there are wide variations in fat affecting body composition. Clearance pathways develop in the fetus before birth. The use of postnatal age as a descriptor of maturation is unsatisfactory because birth may occur prematurely; therefore postmenstrual age is a superior predictor of elimination function. A sigmoid E-max model (Hill equation) describes gradual maturation of clearance in early life leading to a mature adult clearance achieved at a later age.
引用
收藏
页码:303 / 332
页数:30
相关论文
共 152 条
  • [31] FIRST-TIME-IN-HUMAN DOSE SELECTION - ALLOMETRIC THOUGHTS AND PERSPECTIVES
    BOXENBAUM, H
    DILEA, C
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 35 (10) : 957 - 966
  • [32] INTERSPECIES PHARMACOKINETIC SCALING AND THE EVOLUTIONARY-COMPARATIVE PARADIGM
    BOXENBAUM, H
    [J]. DRUG METABOLISM REVIEWS, 1984, 15 (5-6) : 1071 - 1121
  • [33] INTERSPECIES SCALING, ALLOMETRY, PHYSIOLOGICAL TIME, AND THE GROUND PLAN OF PHARMACOKINETICS
    BOXENBAUM, H
    [J]. JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1982, 10 (02): : 201 - 225
  • [34] Brody S., 1934, Univ Mo Agric Exp Sta Res Bull, V220, P1
  • [35] BRODY SAMUEL, 1937, GROWTH, V1, P60
  • [36] Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children
    Capparelli, EV
    Englund, JA
    Connor, JD
    Spector, SA
    McKinney, RE
    Palumbo, P
    Baker, CJ
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (02) : 133 - 140
  • [37] Physiological time
    Carrel, A.
    [J]. SCIENCE, 1931, 74 (1929) : 618 - 621
  • [38] CATZEL P, 1981, PAEDIATRIC PRESCRIBE
  • [39] Physiologically based pharmacokinetic modeling as a tool for drug development
    Charnick, SB
    Kawai, R
    Nedelman, JR
    Lemaire, M
    Niederberger, W
    Sato, H
    [J]. JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1995, 23 (02): : 217 - 229
  • [40] Ontogeny of drug elimination by the human kidney
    Chen, N
    Aleksa, K
    Woodland, C
    Rieder, M
    Koren, G
    [J]. PEDIATRIC NEPHROLOGY, 2006, 21 (02) : 160 - 168